Methods of treating cancer with HDAC inhibitors
View Patent ↗The present invention provides methods of treating cancers, chemoprevention, selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.
1. A method of treating cutaneous T-cell lymphoma in a subject, said method comprising the step of orally administering to the subject a pharmaceutical composition comprising suberoylanilide hydroxamic acid (SAHA) or a pharmaceutically acceptable salt or hydrate thereof, represented by the structure:
and a pharmaceutically acceptable carrier or diluent, wherein the SAHA or the pharmaceutically acceptable salt or hydrate thereof is administered daily at a dose of 400 mg once a day.
2. The method of claim 1 , wherein said composition is contained within a gelatin capsule.
3. The method of claim 1 , wherein said carrier or diluent is microcrystalline cellulose.
4. The method of claim 1 , wherein said composition further comprises sodium croscarmellose as a disintegrating agent.
5. The method of claim 1 , wherein said composition further comprises magnesium stearate as a lubricant.
6. A method of treating cutaneous T-cell lymphoma in a subject, which method comprises the step of orally administering to the subject a pharmaceutical composition comprising suberoylanilide hydroxamic acid (SAHA), represented by the structure:
or a pharmaceutically acceptable salt or hydrate thereof and a pharmaceutically acceptable carrier or diluent, and wherein the SAHA or the pharmaceutically acceptable salt or hydrate thereof is administered at a dose of 300 mg twice daily on a schedule of daily administration for two consecutive weeks, then no administration for one week.
7. The method of claim 6 , wherein said composition is contained within a gelatin capsule.
8. The method of claim 7 , wherein said carrier or diluent is microcrystalline cellulose.
9. The method of claim 8 , wherein said composition further comprises sodium croscarmellose as a disintegrating agent.
10. The method of claim 9 , wherein said composition further comprises magnesium stearate as a lubricant.
11. The method according to claim 1 or claim 6 , wherein said pharmaceutical composition comprises SAHA as the active ingredient.